RCM
KPTI icon

Rotella Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Rotella Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,521
Closed -$698K – 508
2015
Q1 		$698K Buy
+1,521
New +$656K 0.59% 22

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Rotella Capital Management's KPTI Position: Q2 2015 in Review

Rotella Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2015, closing a stake of 1,521 shares — an estimated $698K sold.

Rotella Capital Management first reported a position in KPTI in Q1 2015 and held it in 1 quarter. The position peaked at $698K in Q1 2015. 89 funds tracked by Wall St. Rank hold KPTI as of Q2 2015.

  • Rotella Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Rotella Capital Management sold 1,521 Karyopharm Therapeutics shares in Q2 2015, an estimated $698K.
  • Rotella Capital Management first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 1 quarter.
  • Rotella Capital Management's Karyopharm Therapeutics position peaked at $698K in Q1 2015.
  • 89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2015.

Based on Rotella Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.